H.C. Wainwright analyst Robert Burns raised the firm’s price target on ArriVent Biopharma (AVBP) to $44 from $42 and keeps a Buy rating on the shares. The firm reiterates ArriVent as a top pick, citing the imminent release of top-line data from the pivotal Phase 3 FURVENT trial.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent Biopharma price target raised to $33 from $31 at Citi
- Omega takes new stake in Rocket Companies, exits ArriVent Biopharma
- ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential
- ArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout